A Comparison of Depression Screening Instruments in Hepatitis C and the Impact of Depression on Somatic Symptoms

Sockalingam, Sanjeev; Blank, Diana; Jarad, Abdulqader Al; Alosaimi, Fahad D.; Hirschfield, Gideon M.

doi:10.1016/j.psym.2011.02.006

Cited by 18 publications

(12 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…mood and sleep) conditions amplify fatigue in the medically ill. The relationship between depression and fatigue in previous studies was comparable to the results of the present study [8,[19][20][21]. Notably, previous studies only examined correlations between depression and fatigue or determined the group differences in fatigue between "depressed" and "non-depressed" patients.…”

Section: Discussionsupporting

confidence: 88%

“…Although the above theories have not been tested in patients with HCV infection, the association of depression with fatigue has been established in patients with HCV treated at tertiary liver clinics [8,[19][20][21]. However, the relative contribution of depression to fatigue even in this selected patient population is unclear, since the studies conducted thus far have not included other, theoretically important "secondary" factors (e.g.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The importance of fatigue cognitions in chronic hepatitis C infection

Zalai

Sherman

McShane

et al. 2015

Journal of Psychosomatic Research

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 88%

Section: Introductionmentioning

confidence: 99%

The importance of fatigue cognitions in chronic hepatitis C infection

Zalai

Sherman

McShane

et al. 2015

Journal of Psychosomatic Research

View full text Add to dashboard Cite

“…Recent studies in HCV [32,39], and clinical experiences suggest that depression may be better understood and treated if defined by pathophysiologically related depressive subtypes. Thus, the present study sought to prospectively evaluate the development of depressive symptoms in adults with HCV before and during antiviral therapy to determine their distinctive clinical features and biological correlates.…”

Section: Discussionmentioning

confidence: 99%

Vulnerability to somatic symptoms of depression during interferon-alpha therapy for hepatitis C: A 16-week prospective study

Loftis

Patterson

Wilhelm

et al. 2013

Journal of Psychosomatic Research

View full text Add to dashboard Cite

Objective This study evaluated the distinctive clinical and biological manifestations of depressive symptom subtypes (i.e., cognitive–affective and somatic) in Veterans with hepatitis C viral infection (HCV) before and during interferon-alpha (IFN) based antiviral therapy. Methods Thirty-two Veterans with HCV and no prior history of IFN therapy were followed prospectively during the first 16 weeks of therapy to evaluate depressive symptoms and to determine if baseline cytokine and serotonin levels predicted subsequent changes in depressive scores. Results IFN therapy resulted in a significant increase in total depressive symptoms from baseline (week 0) to week 16, with neurovegetative and somatic symptoms of depression including loss of appetite, fatigue and irritability increasing within the first two weeks of therapy and continuing to increase throughout IFN therapy. When depressive symptoms were evaluated using a two-factor (i.e., Cognitive–Affective and Somatic) model, the Cognitive–Affective factor score did not change significantly following IFN therapy initiation, while the Somatic factor score showed a significant increase from week 0 to week 16. Veterans with the largest increases in somatic symptoms from week 0 to week 2 had significantly higher levels of tumor necrosis factor-alpha (TNF-α) and lower levels of serotonin at baseline, as compared to Veterans with minimal or no increase in somatic symptoms. Conclusion Somatic symptoms of depression can be significantly exacerbated during IFN therapy and may be predicted by higher TNF-α levels and lower serotonin levels at baseline.

show abstract

“…However, free concentrations of R-methadone were unaffected and therefore no dosage adjustment is necessary. Buprenorphine pharmacokinetics are not affected by telaprevir and is safe for coadministration [87]. Boceprevir was studied with methadone, buprenorphine and naloxone.…”

Section: Resultsmentioning

confidence: 99%

“…Using self-report or clinician rated psychiatric scales to measure treatment response to pharmacotherapy can be beneficial in monitoring relapse following psychotropic dose adjustments due to DDIs. For example, both the Beck Depression Inventory-II [89] or Patient Health Questionnaire-9 [87] for depression have been used and validated in this patient population. Further, awareness and education of the entire interdisciplinary treatment team is important in order to assist with prompt recognition of psychiatric symptoms, appropriate selection of psychotropic agents with minimal drug interactions and to minimize adverse effects to increased overall treatment adherence.…”

Section: Discussionmentioning

confidence: 99%

Psychiatric treatment considerations with direct acting antivirals in hepatitis C

et al. 2013

Self Cite

View full text Add to dashboard Cite

BackgroundDespite recent advances in hepatitis C (HCV) treatment, specifically the addition of direct acting antivirals (DAAs), pegylated interferon-alpha remains the backbone of HCV therapy. Therefore, the impact of DAAs on the management of co-morbid psychiatric illness and neuropsychiatric sequalae remains an ongoing concern during HCV therapy. This paper provides a review of the neuropsychiatric adverse effects of DAAs and drug-drug interactions (DDIs) between DAAs and psychiatric medications.MethodsWe conducted a Pubmed search using relevant search terms and hand searched reference lists of related review articles. In addition, we searched abstracts for major hepatology conferences and contacted respective pharmaceutical companies for additional studies.ResultsLimited data is available on the neuropsychiatric adverse effects of DAAs; however, data from major clinical trials suggest that DAAs have minimal neuropsychiatric risk. DAAs can potentially interact with a variety of psychotropic agents via cytochrome P450 and p-glycoprotein interactions. Triazolam, oral midazolam, St. John’s Wort, carbamazepine and pimozide, are contraindicated with DAAs. DDIs between DAAs and antidepressants, anxiolytics, hypnotics, mood stabilizers, antipsychotics and treatments for opioid dependence are summarized.ConclusionsAlthough DAAs do not add significant neuropsychiatric risk, the potential for DDIs is high. Consideration of DDIs is paramount to improving medication adherence and mitigating adverse effects during HCV therapy.

show abstract

A Comparison of Depression Screening Instruments in Hepatitis C and the Impact of Depression on Somatic Symptoms

Cited by 18 publications

References 35 publications

The importance of fatigue cognitions in chronic hepatitis C infection

The importance of fatigue cognitions in chronic hepatitis C infection

Vulnerability to somatic symptoms of depression during interferon-alpha therapy for hepatitis C: A 16-week prospective study

Psychiatric treatment considerations with direct acting antivirals in hepatitis C

Contact Info

Product

Resources

About